Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of theIDASPHEREphase I trial
Alimentary Pharmacology & Therapeutics2014Vol. 39(11), pp. 1301–1313
Citations Over TimeTop 10% of 2014 papers
Mathieu Boulin, Patrick Hillon, Jean–Pierre Cercueil, Franck Bonnetain, S. Dabakuyo, Anne Minello, J L Jouve, Côme Lepage, Marc Bardou, Maëva Wendremaire, Pascal Guérard, Alban Denys, Aurélie Grandvuillemin, Bruno Chauffert, Laurent Bedenne, Boris Guiu
Abstract
Using drug-eluting beads, the maximum-tolerated dose of idarubicin was 10 mg per TACE session. Encouraging responses and median time to progression were observed. Further clinical investigations are warranted (NCT01040559).
Related Papers
- → A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia(1998)161 cited
- → Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia(2021)9 cited
- → Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia(2009)6 cited
- → Therapeutic Activity of 4-Demethoxydauno-Rubicin (Idarubicin) in Adult Acute Leukemia(1983)19 cited
- → Idarubicin(2007)